Featured Story | By Nick Paul Taylor AstraZeneca’s $200 million bet on Ionis Pharmaceuticals’ rare disease drug has delivered an early win. A phase 3 trial of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy hit the mark at an interim analysis, teeing AstraZeneca to make an approval filing that will keep it hot on the heels of Alnylam. read more |
| |
|---|
|
Top Stories By Kevin Dunleavy Visiting Washington, D.C., last week, Axcella CEO Bill Hinshaw is trying to enlist congressional allies to help with long COVID. He’s the first to admit that it’s not an easy sell. read more By Nick Paul Taylor Pfizer is throwing its weight behind Valneva to support late-phase development of a Lyme disease vaccine candidate, agreeing to invest $95.6 million as part of a revised deal that triggered an 81% surge in its partner’s share price. read more By James Waldron One of Merck’s next-generation pneumococcal vaccines has sailed through a mid-stage trial and is being readied for a late-stage study next month. V116—one of three pneumococcal vaccines in Merck’s clinical pipeline—targets serotypes that account for 85% of cases of invasive pneumococcal disease among individuals aged 65 and over in the U.S. read more By Gabrielle Masson Carbon Biosciences has emerged from stealth mode with $38 million in series A funds to push its cystic fibrosis candidate into the clinic and build out its gene therapy platform. read more By Anastassia Gliadkovskaya The order condemned conversion therapy and called on the expansion of access to care, suicide prevention and crisis support services. read more By Gareth Macdonald Many of the 10,000-plus cancer drug studies expected to start over the next few years will be hybrid or decentralized, according to Science 37. The North Carolina trial tech firm made the prediction this week citing a survey of industry executives, 73% of whom plan to execute a site-less or hybrid cancer trial in the next 12 months. read more By Ben Adams Marketing and comms agency VMLY&R won top prizes across the two major healthcare divisions at the Cannes Lions International Festival of Creativity 2022 Monday night for its work with Dell, Intel and Rolls-Royce as well as Maxx Flash mosquito repellent coils. read more By Gareth Macdonald Clinical trial software firm Proofpilot has teamed with Greater Gift, a non-profit that aims to raise awareness about drug research, to encourage both patient diversity and diversity of ideas in studies. read more By Nick Paul Taylor Novartis’ Sandoz is pushing to wipe out an advantage AbbVie’s Humira enjoys over its biosimilar rival in the EU, securing regulatory acceptance of a filing for a high-concentration formulation of the autoimmune treatment. read more By Joseph Keenan AstraZeneca plans to build a manufacturing facility in Qingdau, China, to produce its Breztri aerosol inhalant COPD treatment, which was recently added to the country’s National Reimbursement Drug List. read more By Fraiser Kansteiner GSK has cut the ribbon at its new aseptic smart manufacturing plant in Barnard Castle, England, local news outlet Business Live reported Tuesday. Bankrolled by a £90 million ($110.45 million) investment, the facility—dubbed Q Block—will add another fixture to one of GSK’s biggest U.K. manufacturing sites, the publication said. read more Resources Sponsored by: Blue Matter, strategic consultants in the life sciences Medical Affairs plays a critical role in generating insights to inform strategic decisions, but that role is changing. This paper explores why, and how MA teams can stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored By: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 
